UPTRAVI 400 MCG
SELEXIPAG : 400 MCG · DIN 02451166 · JANSSEN INC
Health Canada status: MARKETED
What is UPTRAVI?
UPTRAVI 400 MCG contains SELEXIPAG : 400 MCG. It is listed in the Health Canada Drug Product Database under DIN 02451166, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Dec-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is UPTRAVI used for?
Long-term treatment of PAH (idiopathic, heritable, associated with connective tissue disorders or congenital heart disease) in adults with WHO FC II–III to delay disease progression.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02451166 |
|---|---|
| Brand name | UPTRAVI |
| Generic / active ingredient | SELEXIPAG : 400 MCG |
| Manufacturer | JANSSEN INC |
| Strength | 400 MCG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AC27 SELEXIPAG |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Dec-2019 |
| Original market date | 2016-04-21 00:00:00 |
How is it administered?
Starting dose 200 mcg twice daily. Titrate by 200 mcg increments weekly to highest tolerated dose, max 1600 mcg twice daily. Reduce frequency to once daily in moderate hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though packaging includes desiccant.
How is it supplied?
Alu/Alu blister with desiccant in cartons of 60 film-coated tablets.
Contraindications
Hypersensitivity to selexipag or any ingredient; Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil).
Warnings and precautions
Vasodilatory effects (hypotension); pulmonary oedema (consider PVOD); hyperthyroidism (monitor thyroid function); increased exposure in moderate hepatic impairment.
What can be used instead?
Other Canadian products sharing ATC code B01AC27 SELEXIPAG. 8 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| UPTRAVI | 1000 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451190 |
| UPTRAVI | 1200 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451204 |
| UPTRAVI | 1400 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451212 |
| UPTRAVI | 1600 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451220 |
| UPTRAVI | 200 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451158 |
| UPTRAVI | 600 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451174 |
| UPTRAVI | 800 MCG | TABLET | JANSSEN INC | MARKETED | DIN 02451182 |
Who else supplies SELEXIPAG worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SELEXIPAG appears in 113 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.